The urokinase-system role of cell proliferation and apoptosis

Histology and Histopathology

Volumn 23, Issue 2, 2008, Pages 227-236

  Hildenbrand, Ralf ^a   Gandhari, Mukesh ^b   Stroebel, Philipp ^a   Marx, Alexander ^a   Allgayer, Heike ^c   Arens, Norbert ^a  

^a UNIVERSITY OF HEIDELBERG   (Germany)

^b JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c UNIVERSITY OF HEIDELBERG   (Germany)

Author keywords

Apoptosis; Cell proliferation; Urokinase; Urokinase receptor

Indexed keywords

CELL SURFACE RECEPTOR; UNCLASSIFIED DRUG; UROKINASE; UROKINASE TYPE PLASMINOGEN ACTIVATOR RECEPTORS; UROKINASE-TYPE PLASMINOGEN ACTIVATOR RECEPTORS;

APOPTOSIS; CELL PROLIFERATION; HUMAN; PHYSIOLOGY; REVIEW;

APOPTOSIS; CELL PROLIFERATION; HUMANS; RECEPTORS, CELL SURFACE; URINARY PLASMINOGEN ACTIVATOR;

EID: 38449118343     PISSN: 02133911     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (89)

1. Alfano D., Franco P., Vocca I., Gambi N., Pisa V., Macini A., Caputi M., Cariro M.V., Iaccarino I. and Stoppelli M.P. (2005). The urokinase plasminogen activator and its receptor: role in cell growth and apoptosis. Thromb. Haemost. 93, 205-211.
2. Alfano D., Iaccarino I. and Stoppelli M.P. (2006). Urokinase signaling through its receptor protects against anoikis by increasing BCL-xL expression levels. J. Biol. Chem. 281, 17758-17767.
3. Andreasen P.A., Nielesen L.S., Kristensen P., Grondahl-Hansen J., Skriver L. and Dano K. (1986). Plasminogen activator inhibitor for human fibrosarcoma cells binds urokinase-type plasminogen activator, but not its proenzyme. J. Biol. Chem. 261, 7644-7651.
4. Andreasen P.A., Kjoller L., Christensen L. and Duffy M.J. (1997). The urokinase-type plasminogen activator system in cancer metastasis: A review. Int. J. Cancer 72, 1-22.
5. Andreasen P.A., Egelund R. and Petersen H.H. (2000). The plasminogen activator system in tumor growth, invasion, and metastasis. Cell Mol. Life Sci. 57, 25-40.
6. Antalis T.M., Clark M.A., Bames T., Lehrbach P.R., Devine P.L., Schevzov G., Goss N.H., Stephens R.W. and Tolstoshev P. (1988). Cloning and expression of a cDNA coding for a human monocyte-derived plasminogen activator inhibitor. Proc. Natl. Acad. Sci. USA 85, 985-989
7. Aguirre Ghiso J.A., Kovalski K. and Ossowski L. (1999). Tumor dormancy induced by downregulation of urokinase receptor in human carcinoma involves integrin and MAPK signaling. J. Cell Biol. 147, 89-104.
8. Aguirre-Ghiso J.A., Liu D., Mignatti A., Kovalski K. and Ossowski L. (2001). Urokinase receptor and fibronectin regulate the ERK(MAPK) to p38(MAPK) activity ratios that determine carcinoma cell proliferation or dormancy in vivo. Mol. Biol. Cell 12, 863-879.
9. Arens N., Gandhari M., Bleyl U. and Hildenbrand R. (2005). In vitro supression of urokinase plasminogen activator in breast cancer cells - a comparison of two antisense strategies. Int. J. Oncol. 26, 113-119.
10. Barnhart B., Legembre P., Pietras E., Bubici C., Franzoso G. and Peter M.E. (2004). CD95 ligand induces motility and invasiveness of apoptosis-resistant tumor cells. EMBO J. 23, 3175-3185.
11. Blasi F. (1988). Surface receptors for urokinase plasminogen activator. Fibrinolysis 2, 73-84.
12. Bohuslav J., Horejsi C., Hansmann J., Stöckl U.H., Weidle O., Majdic I., Bartke W., Knapp A. and Stockinger H. (1995). Urokinase plasminogen activator receptor, ß2-integrin, and src-kinases within a single receptor complex of human monocytes. J. Exp. Med. 181, 1381-1390.
13. Bonni A., Brunet A., West A.E., Datta S.R., Taksu M.A. and Greenberg M.E. (1999). Cell survival promoted by the ras-MAPK signaling pathway bytranscription-dependent and -independent mechanisms. Science 286, 1358-1362.
14. Busso N., Masur S.K., Lazega D., Waxman S. and Ossowski L. (1994). Induction of cell migration by pro-urokinase binding to its receptor: possible mechanism for signal transduction in human epithelial cells. J. Cell Biol. 126, 259-270.
15. Chandrasekar N., Mohanam S., Gujrati M., Olivero W.C., Dinh D.H. and Rao J.S. (2003). Downregulation of uPA inhibits migration and PI3k/Akt signalling in glioblastoma cells. Oncogene 22, 392-400.
16. Chen J., Baskerville C., Han Q., Pan Z.K. and Huang S. (2001). Alpha(v) integrin, p38 mitogen-activated protein kinase, and urokinase plasminogen activator are functionally linked in invasive breast cancer cells. J. Biol. Chem. 276, 47901-47905.
17. Cheng E.H.Y.H., Wei M.C., Weiler S., Flavell R.A., Mak T.W., Lindsten T. and Korsmeyer S.J. (2001). Bcl-2, Bcl-XL Sequester BH3 domain-only molecules preventing BAX- and BAK-mediated mitochondrial apoptosis. Mol. Cell 8, 705-711.
18. Cubellis M.V., Nolli M.L., Cassani G. and Blasi F. (1986). Binding of single-chain prourokinase to the urokinase receptor of human U937 cells. J. Biol. Chem. 261, 15819-15822.
19. Cubellis M.V., Wun T.C. and Blasi F. (1990). Receptor-mediated internalization and degradation of urokinase is caused by its specific inhibitor PAI-1. EMBO J. 9, 1079-1085.
20. Dano K., Andreasen P.A., Gronahl-Hansen J., Kristensen P., Nielsen L.S. and Skriver L.(1985). Plasminogen activators, tissue degradation and cancer. Adv. Cancer Res. 44, 139-266.
21. Del Rosso M., Anichini E., Pedersen N., Blasi F., Fibbi G., Pucci M. and Ruggiero M. (1993). Urokinase-urokinase receptor interaction: non-mitogenic signal transduction in human epidermal cells. Biochem. Biophys. Res. Commun. 190, 347-352.
22. Deng G., Curriden SA., Wang S., Rosenberg S. and Loskutoff DJ. (1996). Is plasminogen activator inhibitor -1 the molecular switch that governs urokinase receptor-mediated cell adhesion and release? J. Cell Biol. 134, 1563-1571.
23. Dumler I., Petri T. and Schleuning W.D. (1993). Interaction of urokinase-type plasminogen activator (u-PA) with its cellular receptor (uPAR) induces phosphorylation on tyrosine of a 38 kDa protein. FEBS Lett. 322, 37-40.
24. Dumler I., Weis A., Mayboroda O.A., Maasch C., Jerke U., Haller H. and Gulba D.C. (1998). The JAK/STAT pathway and urokinase receptor signaling in human vascular smooth muscle cells. J. Biol. Chem. 273, 315-321.
25. Fischer K., Lutz V., Wilhelm O., Schmitt M., Graeff H., Heiss P., Nishiguchi T., Harbeck N., Kessler H., Luther T., Magdolen V. and Reuning U. (1998). Urokinase induces proliferation of human ovarian cancer cells: characterization of structural elements required for growth factor function. FEBS Lett. 438, 101-105.
26. Gandhari M., Arens N., Majety M., Dorn-Beineke A. and Hildenbrand R. (2006). Urokinase-type plasminogen activator induces proliferation in breast cancer cells. Int. J. Oncol. 28, 1463-1470.
27. Guillonneau X., Bryckaert M., Launay-Longo C., Courtis Y. and Mascarelli F. (1998). Endogenous FGF1-induced activation and synthesis of extracellular signal-regulated kinase II reduce cell apoptosis in retinal-pigmented epithelial cells. J. Biol. Chem. 273, 22367-22373.
28. Gunzler W.A., Steffens G.J., Otting F., Kim S.M., Frankus E. and Flohe L. (1982). The primary structure of high molecular mass urokinase from human urine. The complete amino acid sequence of the A chain. Hoppe Seylers Z. Physiol. Chem. 363, 1155-1165.
29. Gutierrez L.S., Schulman A., Brito-Robinson T., Noria F., Poplis V.A. and Castellino F.J. (2000). Tumor development is retarded in mice lacking the gene for urokinase-type plasminogen activator or its inhibitor, plasminogen activator inhibitor-1. Cancer Res. 60, 5839-5847.
30. Gyetko M.R., Sud S., Chen G.H., Fuller J.A., Chensue S.W. and Toews G.B. (2002). Urokinase-type plasminogen activator is reqired for the generation of a type 1 immune response to pulmonary cryptococcus neoformans infection. J. Immunol. 168, 801-809.
31. Harbeck N., Kates R.E., Gauger K., Willems A., Kiechle M., Magdolen V. and Schmitt M. (2004). Urokinase-type plasminogen activator (uPA) and its inhibitor PAI-I: novel tumor-derived factors with a high prognostic and predictive impact in breast cancer. Thromb. Haemost. 91, 450-456.
32. Harbeck N., Kates R.E., Look M.P., Meijer-van Gelder M.E., Klijn J.G.M., Krüger A., Kiechle M., Jänicke F., Schmitt M. and Foekens J.A. (2002). Enhanced benefit from adjuvant chemotherapy in breast cancer patients classified high-risk according to urokinase-type plasminogen activator (uPA) and plasminogen activator inhibitor type-1. Cancer Res. 62, 4617-4622.
33. Herbert J.M., Lamarche I. and Carmeliet P. (1997). Urokinase and tissue-type plasminogen activator are required for the mitogenic and chemotactic effects of bovine fibroblast growth factor and platelet-derived growth factor-BB for vascular smooth muscle cells. J. Biol. Chem. 272, 23585-23591.
34. Hildenbrand R. and Arens N. (2004). Protein and mRNA expression of uPAR and PAI-1 in myoepithelial cells of early breast cancer lesions and normal breast tissue. Br. J. Cancer 91, 564-71.
35. Hildenbrand R., Dilger I., Hörlin A. and Stutte H.J. (1995). Urokinase and macrophages in tumor angiogenesis. Br. J. Cancer 72, 818-823.
36. Hildenbrand R., Wolf G., Bohme B., Bleyl U. and Steinborn A. (1999). Urokinase plasminogen activator receptor (CD87) expression of tumor-associated macrophages in ductal carcinoma in situ, breast cancer, and resident macrophages of normal breast tissue. J. Leukocyte Biol. 66, 40-49.
37. Kanse S.M., Benzakour O., Kanthou C., Kost C., Lijnen H.R. and Preissner K.T. (1997). Induction of vascular SMC proliferation by urokinase indicates a novel mechanism of action in vasoproliferative disorders. Arterioscler. Thromb. Vasc. Biol. 17, 2848-2854.
38. Khwaja A., Rodriguez-Viciana P., Wennstrom S., Warne P.H. and Downward J. (1997). Matrix adhesion and Ras transformation both activate a phosphoinositide 3-OH kinase and protein kinase B/Akt cellular survival pathway. EMBO J. 16, 2783-2793.
39. Kirchheimer J.C., Wojta J., Christ G., Hienert G. and Binder B.R. (1988). Mitogenic effect of urokinase on malignant and unaffected adjacent human renal cells. Carcinogenesis 9, 2121-2123
40. Kirchheimer J.C., Wojta J., Christ G. and Binder B.R. (1989). Functional inhibition of endogenously produced urokinase decreases cell proliferation in a human melanoma cell line. Proc. Natl. Acad. Sci. USA 86, 5424-5428.
41. Koopman J.L., Slomp J., Anton C.W., de Bart W, Quax P.H.A. and Verheijen J.H. (1998). Mitogenic effects of urokinase on melanoma cells are independent of high affinity binding to the urokinase receptor. J. Biol. Chem. 273, 33267-33272.
42. Koshelnick Y., Ehart M., Hufnagl P., Heinrich P.C. and Binder B.R. (1997). Urokinase receptor is associated with the components of the JAK1/STAT1 signaling pathway and leads to activation of this pathway upon receptor clustering in the human kidney epithelial tumor cell line TCL-598. J. Biol. Chem. 272, 28563-28567.
43. Krishnamoorthy B., Darnay B., Aggarwal B., Dinh D.H., Kouraklis G., Olivero W.C., Gujrati M. and Rao J.S. (2001). Glioma cells deficient in urokinase plasminogen activator receptor expression are susceptible to tumor necrosis factor-alpha-related apoptosis-inducing ligand-induced apoptosis. Clin. Cancer Res. 7, 4195-4201.
44. Laufs S., Schumacher J. and Allgayer H. (2006). Urokinase-receptor (u-PAR): An essential player in multiple games of cancer: a review on its role in tumor progression, invasion, metastasis, proliferation/ dormancy, clinical outcome and minimal residual disease. Cell Cycle 16, 1760-1771.
45. Liotta L.A., Steeg P.S. and Stetler-Stevenson W.G. (1991). Cancer metastasis and angiogenesis: An imbalance of positive and negative regulation. Cell 64, 327-336.
46. Liu D., Aguirre Ghiso J., Estrada Y. and Ossowski L. (2002). EGFR is a transducer of the urokinase receptor initiated signal that is required for in vivo growth of a human carcinoma. Cancer Cell 1, 445-457.
47. Llinas P., Le Du M.H., Gardsvoll H., Dano K., Ploug M., Gilquin B., Stura E.A. and Menez A. (2005). Crystal structure of the human urokinase plasminogen activator receptor bound to an antagonist peptide. EMBO J. 24, 1655-1663.
48. Ludwig T. (2005). Local proteolytic activity in tumor cell invasion and metastasis. Bioassays 27, 1181-1191.
49. Manchanda N. and Schwartz B.S. (1995). Interaction of single-chain urokinase and plasminogen activator inhibitor type-1. J. Biol. Chem. 270, 20032-20035.
50. Ma Z., Webb D.J., Jo M. and Gonias S.L. (2001). Endogenously produced urokinase-type plasminogen activator is a major determinant of the basal level of activated ERK/MAP kinase and prevents apoptosis in MDA-MB-231 breast cancer cells. J. Cell Sci. 114, 3387-3396.
51. Meijer-van Gelder M.E., Look M.E., Peters H.A., Schmitt M., Brünner N., Harbeck N., Klijn J.G.M. and Foekens J.A. (2004). Urokinase-type plasminogen activator system in breast cancer: Association with tamoxifen therapy in recurrent disease. Cancer Res. 64, 4563-4568.
52. Nguyen D.H.D., Catling A.D., Webb D.J., Synakovic M., Walker L.A., Somlyo A.V., Weber M.J. and Gonias S. (1999). Myosin light chain kinase functions downstream of Ras/ERK to promote migration of urokinase-type plasminogen activator-stimulated cells in an intergrin-selective manner. J. Cell Biol. 146, 149-164.
53. Nip J., Strom D.K., Fee B.E., Zambetti G., Cleveland J.L. and Hiebert S.W. (1997). E2F-1 cooperates with topoisomerase II inhibition and DNA damage to selectively augment p53-independent apoptosis. Mol. Cell Biol. 17, 1049-1056.
54. Ny T., Sawdey M., Lawrence D., Millan J.L. and Loskutoff D.J. (1986). Cloning and sequence of a cDNA coding for the human beta-migrating endothelial-cell-type plasminogen activator inhibitor. Proc. Natl. Acad. Sci. USA 83, 6776-6780.
55. Olson D., Pollanen J., Hoyer-Hansen G., Ronne E., Sakaguchi K., Wun T.C., Appella E., Dano K. and Blasi F. (1992). Internalization of the urokinase-plasminogen activator inhibitor type-1 complex is mediated by the urokinase receptor. J. Biol. Chem. 267, 9129-9133.
56. Ploug M. (2003). Structure-function relationships in the interaction between the urokinase-type plasminogen activator and its receptor. Curr. Pharm. Des. 9, 1499-1528.
57. Ploug M. and Ellis V. (1994). Structure-function relationships in the receptor for urokinase-type plasminogen activator. Comparison to other members of the Ly-6 family and snake venom alpha-neurotoxins. FEBS Lett. 349, 163-168.
58. Ploug M., Rønne E., Behrendt N., Jensen A.L, Blasi F. and Danø K. (1991). Cellular receptor for urokinase plasminogen activator. Carboxyl-terminal processing and membrane anchoring by glycosyl-phosphatidylinositol. J. Biol. Chem. 266, 1926-1933
59. Ploug M., Gardsvoll H., Jorgenson T.J., Lonborg H.L. and Dano K. (2002). Structural analysis of the interaction between urokinase-type plasminogen activator and its receptor: A potential target for anti-invasive cancer therapy. Biochem. Soc. Trans. 30, 177-183.
60. Rabbani S.A., Mazar A.P., Bernier S.M., Haq M., Bolivar I., Henkin J. and Goltzman D. (1992). Structural requirements for the growth factor activity of the amino-terminal domain of urokinase. J. Biol. Chem. 267, 14151-14156.
61. Rabbani S.A., Desjardins J., Bell A.W., Banville D., Mazar A.P., Henkin J. and Goltzman D (1990). An aminoterminal fragment of urokinase isolated from a prostate cancer cell line (PC-3) is mitogenic for osteoblast-like cells. Biochem. Biophys. Res.Commun. 173, 1058-1064.
62. Reuning U., Magdolen V., Wilhelm O., Fischer K., Lutz K., Graeff H. and Schmitt M (1998). Multifunctional potential of the plasminogen activation system in tumor invasion and metastasis. Int. J. Oncol. 13, 893-906.
63. Roldan A.L., Cubellis M.V., Masucci M.T., Behrendt N., Lund L.R., Dano K., Appella E. and Blasi F. (1990). Cloning and expression of the receptor for human urokinase plasminogen activator, a central molecule in cell surface, plasmin dependent proteolysis. EMBO. J. 9, 467-474.
64. Romer J., Nielsen B.S. and Ploug M. (2004). The urokinase receptor as a potential target in cancer therapy. Curr. Pharm. Des. 10, 2359-2376.
65. Roselli H.T., Su M., Washington K., Kerins D.M., Vaughan D.E. and Russell W.E. (1998). Liver regeneration is transiently impaired in urokinase-deficient mice. Am. J. Physiol. 275, G1472-G1479.
66. Schmitt M., Jaenicke F., Moniwa N., Chucholowski N., Pache L. and Graeff H. (1992). Tumor-associated urokinase-type plasminogen activator: biological and clinical significance. Biol. Chem. Hoppe Seyler 373, 611-622.
67. Shapiro R.L., Duquette J.G., Roses D.F., Nunes I., Harris M.N., Kamino H., Wilson E.L. and Rifkin D.B. (1996). Induction of primary cutaneous melanocytic neoplasms in urokinase-type plasminogen activator (uPA)-deficient and wild-type mice: cellular blue nevi invade but do not progress to malignant melanoma in uPA-deficient animals. Cancer Res. 56, 3597-3604.
68. Shenoy-Scaria A.M., Kwong J., Fujita T., Olszowy M.W., Shaw A.S. and Lublin D.M. (1992). Signal transduction through decay-accelerating factor. Interaction of glycosyl-phosphatidylinositol anchor and protein tyrosine kinases p56lck and p59fyn 1. J. Immunol. 149, 3535-3541.
69. Sitrin R.G., Pan P.M., Blackwood R.A., Huang J. and Petty H.R. (2001). Cutting edge: evidence for a signaling partnership between urokinase receptors (CD87) and L-selectin (CD62L) in human polymorphonuclear neutrophils. J. Immunol. 166, 4822-4825.
70. Stefanova I., Corcoran M.L., Horak E.M., Wahl L.M., Bolen J.B. and Horak I.D. (1993). Lipopolysaccharide induces activation of CD14-associated protein tyrosine kinase p53/56lyn. J. Biol. Chem. 268, 20725-20728.
71. Stoppelli M.P., Corti A., Soffientini A., Cassani G., Blasi F and Assoian R.K. (1985). Differentiation-enhanced binding of the amino-terminal fragment of human urokinase plasminogen activator to a specific receptor on u937 monocytes. Proc. Natl. Acad. Sci. USA 82, 4939-4943.
72. Stoppelli M.P., Tacchetti C., Cubellis M.V., Corti A., Heating V.J., Cassani G., Appella E. and Blasi F. (1986). Autocrine saturation of pro-urokinase receptors on human A431 cells. Cell 45, 675-684.
73. Suelves M., Lopez-Alemany R., Lluis, F., Aniorte G., Serrano E., Parra M., Carmeliet P. and Munoz-Canoves P. (2002). Plasmin is required for myogenesis in vitro and skeletal muscle regeneration in vivo. Blood 99, 2835-2844.
74. Tang H., Kerins D.M., Hao Q., Inagami T. and Vaughan D.E. (1998). The urokinase-type plasminogen activator receptor mediates tyrosine phosphorylation of focal adhesion proteins and activation of meitogen-activated protein kinase in cultured endothelial cells. J. Biol. Chem. 273, 18268-18272
75. Terada K., Kaziro Y. and Satoh T. (2000). Analysis of ras-dependent signals that prevent caspase-3 activation and apoptosis induced by cytokine deprivation in hematopoietic cells. Biochem. Biophys. Res. Commun. 267, 449-445
76. Trisciuoglio D., Iervolino A., Candiloro A., Fibbi G., Fanciulli M., Zangemeister-Wittke U., Zupi G. and Del Bufalo D. (2004). Bcl-2 induction of urokinase plasminogen activator receptor expression in human cancer cells through Sp1 activation. J. Biol. Chem. 279, 6737-6745
77. Vassalli J.D., Dayer J.M., Wohlwend A. and Belin D. (1984). Concomitant secretion of prourokinase and of plasminogen activator-specific inhibitor by cultured human monocytes-macrophages. J. Exp. Med. 159, 1653-1668.
78. Webb D.J., Nguyen D.H.D., Sankovic M. and Gonias S.L. (1999). The very low density lipoprotein receptor regulates urokinase receptor catabolism and breast cancer cell motility in vitro. J. Biol. Chem. 274, 7412-7420.
79. Webb D.J., Nguyen D.H.D. and Gonias S.L. (2000). Extracellular signal-regulated kinase functions in the urokinase receptor-dependent pathway by which neutralization of low density lipoprotein receptor-related protein promotes fibrosarcoma cell migration and matrigel invasion. J. Cell Sci. 113, 123-134.
80. Wei M.C., Zong W.X., Cheng E.H.Y., Lindsten T., Panoutsakopoulou V., Ross A.J., Roth K.A., MacGregor G.R., Thompson C.B. and Korsmeyer S.J. (2001). Proapoptotic BAX and BAK: A requisite gateway to mitochondrial dysfunction and death. Science 292, 727-730
81. Wei Y., Waltz D.A., Rao N., Drummond R.J., Rosenberg S. and Chapman H.A. (1994). Identification of the urokinase receptor as an adhesion receptor for vitronectin. J. Biol. Chem. 269, 32380-32388
82. Wei Y., Lukashev M., Simon D.I., Bodary S.C., Rosenberg S., Doyle M.V. and Chapman H.A. (1996) Regulation of integrin function by the urokinase receptor. Science 273, 1551-1555
83. Wei Y., Yang X., Liu Q., Wilkins J.A. and Chapman H.A. (1999). A role for caveolin and the urokinase receptor in integrin-mediated adhesion and signaling. J. Cell Biol. 144, 1285-1294
84. Wei Y., Eble J.A., Wang Z., Kreidberg J.A., Chapman H.A. (2001). Urokinase receptors promote beta1 integrin function through interactions with integrin alpha3beta1. Mol. Biol. Cell 12, 2975-2986
85. Wick W., Wagner S., Kerkau S., Dichgans J., Tonn J.C. and Weller M (1998). Bcl-2 promotes migration and invasivesness of human glioma cells. FEBS lett. 440, 419-424.
86. Wun T.C., Schleuning W.D. and Reich E. (1982). Isolation and characterization of urokinase from human placenta. J. Biol. Chem. 257, 3276-3283.
87. Xia Z., Dickens M., Raingeaud J., Davis R.J. and Greenberg M.E. (1995). Opposing effects of ERK and JNK-38 MAP kinases on apoptosis. Science 270, 1326-1331
88. Yanamandra N., Konduri S.D., Mohanam S., Dinh D.H., Olivero W.C., Gujrati M., Nicolson G.L., Obeyeseke M. and Rao J.S. (2001). Downregulation of urokinase-type plasminogen activator receptor (uPAR) induces caspase-mediated cell death in human glioblastoma cells. Clin. Exp. Metastasis 18, 611-615
89. Ye R.D., Ahern S.M., Le Beau M.M., Lebo R.V. and Sadler J.E. (1989). Structure of the gene for human plasminogen activator inhibitor-2. The nearest mamalian homologue of chicken ovalbumin. J. Biol. Chem. 264, 5495-5502.